Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645069 · ClinicalTrials.gov registry record · Phase 1
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by Adagene.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT04645069 is a Phase 1 study that has completed, run by Adagene. The registered enrollment target is 58 participants.
The verdict
NCT04645069, a Phase 1 study, has completed, sponsored by Adagene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .
Interventions
- BIOLOGICAL ADG126 Mono
- BIOLOGICAL ADG126-anti PD1
- BIOLOGICAL ADG126-ADG106
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04645069
The ClinicalTrials.gov registry entry for NCT04645069 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adagene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ADG126 Mono is the first listed.
NCT04645069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04645069 about?
NCT04645069 is a clinical study titled "ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors". ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .
What is the current status of trial NCT04645069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2021-03-15. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT04645069?
The interventions under investigation include: ADG126 Mono (BIOLOGICAL), ADG126-anti PD1 (BIOLOGICAL), ADG126-ADG106 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04645069?
This trial is sponsored by Adagene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.